Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on September 17, 2025
MET Florida Partners With Southern Sassafras Marketing To Strengthen Healthcare IT And Branding
New partnership combines HIPAA-compliant IT services from MET Florida with branding and marketing expertise from Southern Sassafras Marketing. FORT MYERS, FL, UNITED STATES, September 17, 2025 /EINPresswire.com/ -- MET Florida Partners with Southern …
Palm Beach Orthopaedic Institute Introduces Smart Knee Implant
New technology brings data-driven insights to total knee replacement patients. WEST PALM BEACH, FL, UNITED STATES, September 17, 2025 /EINPresswire.com/ -- Palm Beach Orthopaedic Institute is proud to announce it is now offering Persona IQ®, the world’s …
Rising Diabetes Rates in Americans with Disabilities Fuel Demand for Improvements in Care
Enhancements in patient monitoring and provider training are needed to improve the health of disabled Americans with diabetes. CLEARWATER, FL, UNITED STATES, September 17, 2025 /EINPresswire.com/ -- As diabetes cases continue to rise nationwide, people …
Feather In Her Cap Award Nominations Open. Organization Adds New Award to Recognize Animal Health ‘Champions of Women’
Nominations open for four awards, including new recognition honoring advocates of any gender supporting women’s advancement in animal health ORLANDO, FL, UNITED STATES, September 17, 2025 /EINPresswire.com/ -- The Feather in Her Cap Association, Inc., …
Novo Nordisk’s oral semaglutide 25 mg (Wegovy® in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study
Oral semaglutide 25 mg (the once-daily pill formulation of Wegovy®) achieved significant weight loss, with one in three study participants losing 20% or more body weight1** Oral semaglutide 25 mg also demonstrated improvements in the ability to perform …
Bionano Genomics, Inc. Announces Closing of $10 Million Public Offering
SAN DIEGO, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) (“Bionano” or the “Company”) today announced the closing of its previously announced public offering of an aggregate of 5,000,000 shares of the Company’s common stock (or …
Eagle Pharmaceuticals Announces Availability of Proxy Materials and Audited Financial Statements for the 2023 and 2024 Fiscal Years
WOODCLIFF LAKE, N.J., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced the availability of proxy materials for its 2025 Annual Meeting of Stockholders, which is scheduled to be held …
Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation
Arvinas and Pfizer plan to jointly select third party for the out-licensing and commercialization of vepdegestrant Additional cost optimization measures expected to realize total annual savings of more than $100 million compared to FY 2024 Board authorizes …
Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe
Postpartum depression is a leading cause of maternal mortality in Europe1-2, and is one of the most common medical conditions associated with pregnancy3-5; up to 20% of women experience postpartum depressive symptoms6-11 The approval of this new …
NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1
Data show a favorable safety profile and early efficacy signals in a heavily pre-treated population whose cancer progressed after multiple prior lines of therapy including anti-PD-1 Recommended phase 2 dose (RP2D) established at 33% of gross tumor volume ( …
NANOBIOTIX annonce de nouveaux résultats de Phase 1 évaluant JNJ-1900 (NBTXR3) en combinaison avec des inhibiteurs de points de contrôle en traitement de deuxième ligne ou plus chez des patients atteints de mélanome cutané résistant aux anti-PD-1
Les données ont montré un profil de sécurité favorable et des signaux préliminaires d’efficacité dans une population lourdement prétraitée dont le cancer était en progression malgré plusieurs lignes de traitement, incluant des anti-PD-1. La dose …
Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM
CAMBRIDGE, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that 48-week clinical data from the Phase 3 study in China evaluating …
CooperCompanies Announces Expanded Share Repurchase Program
SAN RAMON, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today its Board of Directors has approved a $1 billion increase in the Company’s share repurchase program. The share …
Regional Health Properties, Inc. Completes Repurchases of 12.5% Series B Cumulative Redeemable Preferred Shares
Atlanta, GA, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (“Regional”) (OTCQB: RHEP) (OTCQB: RHEPA) (OTCQB: RHEPB) (OTCQB: RHEPZ) today announced it has completed the repurchase of 366,359 shares of its 12.5% Series B Cumulative …
Vaxart Appoints W. Mark Watson as Lead Independent Director
In process of adopting a Director stock ownership policy to reinforce commitment of aligning the Board’s interests with stockholders Vaxart encourages all stockholders of record on July 29, 2025, who have not yet voted FOR the reverse stock split, to do so …
Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update
REDWOOD CITY, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today reported financial results and …
Joint Commission and Coalition for Health AI (CHAI) Release Initial Guidance to Support Responsible AI Adoption Across U.S. Health Systems
OAKBROOK TERRACE, Illinois, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Today, Joint Commission and the Coalition for Health AI (CHAI) released the first installment of their work together – Guidance on Responsible Use of AI in Healthcare, which will serve as …
Buying Guide to the Top & Most Effective Beetroot Supplements 2025: Pills and Powder By MushCanyon
Washington DC, Sept. 17, 2025 (GLOBE NEWSWIRE) -- MushCanyon is excited to present The Ultimate Guide to Best Beetroot Supplements 2025: Pills and Powder—an in-depth exploration of beetroot’s powerful benefits and how to choose premium formulations whether …
VELA Medical USA Highlights Projected U.S. Ophthalmology Workforce Shortage by 2035
With ophthalmology projected to fall to just 70% adequacy by 2035, VELA Medical USA calls for solutions that safeguard staff and streamline clinics. TAMPA, FL, UNITED STATES, September 17, 2025 /EINPresswire.com/ -- The U.S. ophthalmology workforce is …
Are Women on the Frontline of Antimicrobial Resistance?
LONDON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- National Patient Survey of Women’s Urinary Tract Infection (UTI) and Prenatal Screening reveals women suffering from UTI concerned about immediate antibiotic prescribing and Antimicrobial Resistance (AMR), …